Solara Active Pharma Sciences Ltd. Share Price

Overview

Solara Active Pharma Sciences Ltd. share price is currently ₹607.17, up by ₹0.29 (0.05%) from its previous closing price of ₹606.88. The share price has declined -17.47% over the past month and gained 6.66% over the past year. The stock's 52-week low and high are ₹413.10 and ₹759.75, respectively. Solara Active Pharma Sciences Ltd. has a market capitalisation of ₹ 3,350.00 Cr. The share price was last updated on 23 Oct 2026, 03:55 PM IST.

Solara Active Pharma Sciences Ltd.
Solara Active Pharma Sciences Ltd.
SOLARA
 ₹0.00
 ₹0.29
0.05%
Healthcare
 ₹0.00(%)1D

Updated: 23 Oct 2026, 03:55:36 pm IST

Market Data

Open Price

 ₹618.42

Prev. Close

 ₹606.88
 ₹588.35

Day Low

 ₹628.77

Day High

 ₹413.10

52 Week Low

 ₹759.75

52 Week High

HealthcarePharmaceuticals & Drugs
CategorySmall Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

80.53

Sector PE

42.08

PB Ratio

2.17

Sector PB

5.48

EPS

7.54

Dividend Yield

0.00

Today's Volume

528.037 K

5 Day Avg. Volume

1.681 M

PEG Ratio

-0.06

Market Cap.

₹ 3,350.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Corporate Actions will be available shortly.

Mutual Fund Ownership

Mutual Fund Holder
Aug 26
Shares held
Sep 26
Shares held
Aditya Birla Sun Life Flexi Cap Fund - Regular Plan - Growth4.20 Lac
4.20 Lac
no change
Motilal Oswal BSE Healthcare ETF625
679
(8.64%)
Bandhan BSE Healthcare Index Fund - Regular Plan - Growth294
320
(8.84%)
Motilal Oswal BSE 1000 Index Fund - Regular Plan - Growth68
72
(5.88%)

About Solara Active Pharma Sciences Ltd. 👋

Solara Active Pharma Sciences Limited is an India-based global, pureplay active pharmaceutical ingredients (API) company. The Company is engaged in the manufacturing and development of APIs and offers contract manufacturing and development services for global companies. Its commercial product category includes Albendazole, Aprepitant (Antiemetic), Colchicine, Citicoline Sodium, Disulfiram, Dolutegravir, Etomidate, Flucytosine, Ibuprofen Arginine, Lurasidone Hydrochloride, Rifaximin, Tioconazole, Zileuton and others. Its research and development (R&D) product category includes Brivaracetam, Flecainide Acetate, Naproxen Base, Obeticholic acid, Patiromer Sorbitex Calcium, Rotigotine, Safinamide, Sapropterin, Sugammadex, Tranexamic Acid, Sucroferric Oxyhydroxide and others. Its business is spread across 70 countries with operations in the key markets of North America, Europe, Japan, South Korea and the Middle East and North Africa. It has one R&D center in Chennai.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Sneha M Vasudeo

Sneha M Vasudeo

18 Oct • 7:53 PM · SEBI-Registered Analyst

Weak Profitability Amid a Positive Long-Term Technical Trend

SOLARA
Company Overview → Indian pharmaceutical company specializing in the manufacturing of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. → Caters to multiple therapeutic segments, including cardiology, diabetes and oncology. → Focuses on research and development, product quality and compliance with international manufacturing standards. → Serves domestic and international markets through its pharmaceutical manufacturing capabilities. Financial & Fundamental Analysis → Operating Revenue: ₹1,431.43 Cr (TTM). → Revenue Growth: 6% annually, indicating modest growth. → Pre-tax Margin: -1%, reflecting weak profitability and the need for improvement. → ROE: Approximately 0%, indicating negligible returns on shareholders’ capital. → Debt-to-Equity: 9%, suggesting relatively low financial leverage. Technical Analysis → Trading close to its 50-day moving average (50 DMA), making this a key support level to monitor. → Comfortably above its 200-day moving average (200 DMA), approximately 17% higher, indicating a positive longer-term technical trend. → Needs to sustain support around the 50 DMA to maintain its near-term upward momentum. → Technical View: The stock has a constructive longer-term technical setup, supported by its position above the 200 DMA. However, weak profitability and modest revenue growth remain key fundamental concerns. Holding the 50 DMA would be important for sustaining the current momentum. Disclaimer: For informational and educational purposes only. This is not investment advice or a recommendation to buy or sell securities.

See More
DHARMESH BHATT             R A

DHARMESH BHATT R A

15 Sep • 12:49 AM · SEBI-Registered Analyst

BUY AT DIP STRATEGY POSITIVE STOCK— SOLARA Acive pharma

SOLARA
SOLARA : CMP 749.85 (11.09.2026) Important Support level : 720-725 , this level may play an important role to push prices upside further . *The stock demonstrates strong price momentum, with recent price action showing consistent higher highs and higher lows. *Volume has been increasing, suggesting active participation and growing investor interest on the buy side. Key technical indicators such as the Relative Strength Index (RSI) and Moving Averages (e.g., 20/50 EMA) confirm a bullish trend. *The stock is trading near its Daily high, indicating buying strength and the potential for a breakout. * No significant resistance was observed near weekly close Stodk also has overall all sectorial support

See More
Hemraj Singh Sikarwar

Hemraj Singh Sikarwar

14 Sep • 9:14 PM · SEBI-Registered Analyst

STOCK IN NEWS | SOLAR INDUSTRIES INDIA is in focus

SOLARA
Industries India is in focus after the company announced a major overseas expansion through the acquisition of Omnia Holdings in South Africa for approximately US$1.355 billion, or around ₹12,951 crore. The transaction is significant in scale and could substantially expand Solar Industries’ international presence. Omnia Holdings has businesses across mining chemicals, agriculture and related industrial segments, giving Solar Industries an opportunity to diversify its global operations. For investors, however, the size of the acquisition is only one part of the story. The key question is whether the acquisition can generate attractive returns on the capital being deployed. Investors will need to monitor the funding structure, leverage, integration process, profitability of the acquired business and the potential impact on consolidated earnings. Solar Industries already has an established position in industrial explosives and defence-related products. The acquisition could therefore strengthen its international footprint and provide access to new markets. At the same time, large acquisitions bring execution and balance-sheet risks. Currency movements, integration challenges and the ability to maintain margins across a much larger international business will be important factors to watch. Key factors to monitor: • Acquisition funding and debt levels • Integration of Omnia Holdings • Revenue and margin contribution • International business growth • Return on invested capital • Impact on consolidated earnings Key takeaway: A large acquisition can accelerate growth, but ultimately the success of the deal will depend on disciplined capital allocation and the returns generated from the acquired business. Stock in News does not mean Buy/Sell Call. This post is for educational and informational purposes only and is not investment advice or a recommendation to buy or sell any security.

See More
AKANSHA JAIN

AKANSHA JAIN

14 Sep • 5:07 PM · SEBI-Registered Analyst

Solar Industries India | Stock in Focus – September 14, 2026

SOLARA
ar Industries Announces ₹12,951 Crore Acquisition of Omnia Holdings Solar Industries India is in focus after announcing a landmark agreement to acquire **Omnia Holdings**, a South African explosives and chemicals group, for approximately **₹12,951 crore**. The acquisition represents a major step in Solar Industries’ international expansion and significantly strengthens its presence across the mining explosives, chemicals and defence-related value chain. The transaction gives the company access to Omnia’s established operations and customer base across multiple international markets. The deal is particularly significant because mining and infrastructure activity is driving demand for commercial explosives globally, while Solar Industries has been simultaneously expanding its defence manufacturing capabilities in India. **Why does it matter?** The acquisition can potentially diversify Solar Industries’ revenue base beyond India and provide access to international mining markets. It could also create opportunities for operational synergies, technology sharing and cross-selling. However, the size of the transaction makes **funding, leverage, integration and return on capital** important factors for investors to monitor. **Key things to watch:** 1. Funding structure and impact on debt 2. Omnia's revenue and profitability contribution 3. Integration of international operations 4. Mining explosives demand 5. Defence order-book growth in India 6. Post-acquisition return on capital

See More
CA Sumit Mangla

CA Sumit Mangla

7 Sep • 2:02 PM · SEBI-Registered Analyst

Morepen Labs Completes Phase-1 Capacity Expansion

MOREPENLAB
has successfully completed the first phase of its manufacturing capacity expansion programme ahead of schedule. The company’s installed reactor capacity for API and CDMO operations has increased from 535 KL to 614 KL. The early completion of this phase strengthens Morepen’s ability to support growing demand in its active pharmaceutical ingredients and contract development and manufacturing organisation businesses. The expansion forms part of a multi-phase roadmap aimed at scaling capacity to meet larger global CDMO opportunities and higher-value manufacturing requirements. By enhancing reactor capacity ahead of schedule, Morepen is better positioned to execute on existing mandates and pursue additional partnerships. The development underscores the company’s focus on operational readiness and timely infrastructure upgrades to support its growth strategy in the pharmaceutical manufacturing space. *Top stocks in the API & CDMO industry:* Laurus Labs, Divi’s Laboratories, and Solara Active Pharma Sciences.

See More
DEEPAK PAL

DEEPAK PAL

28 Aug • 12:30 PM · SEBI-Registered Analyst

“क्या है Golden Crossover Strategy? कमाएगी या फंसाएगी?”

अगर आप Technical Analysis सीख रहे हैं, तो आपने Golden Crossover का नाम जरूर सुना होगा। यह एक ऐसा technical signal है जिसे traders अक्सर long-term bullish trend की शुरुआत के संकेत के रूप में देखते हैं। लेकिन Golden Crossover आखिर होता क्या है? ----->Golden Crossover क्या होता है? जब किसी stock या index की short-term moving average, उसकी long-term moving average को ऊपर की तरफ cross करती है, तो इसे Golden Crossover कहा जाता है। सबसे popular combination है: 50-Day Moving Average > 200-Day Moving Average यानी जब: 50 DMA, 200 DMA को नीचे से ऊपर cross करे तो इसे Golden Crossover कहा जाता है। ##इसे Bullish Signal क्यों माना जाता है? 50 DMA short-term price trend को दिखाता है। 200 DMA long-term trend को दिखाता है। जब 50 DMA, 200 DMA के ऊपर चला जाता है, तो इसका मतलब है कि: Short-Term Momentum ↑ और Long-Term Trend मजबूत होने लगा है इसलिए traders इसे संभावित trend reversal या new uptrend का संकेत मानते हैं। ------>Golden Crossover के 3 Important Stages Stage 1 — Downtrend Price कमजोर होता है और short-term average long-term average के नीचे रहता है। Stage 2 — Recovery Price में buying शुरू होती है और 50 DMA तेजी से ऊपर आने लगता है। Stage 3 — Golden Crossover 50 DMA, 200 DMA को ऊपर की तरफ cross करता है। यहीं से traders bullish trend की संभावना पर ध्यान देना शुरू करते हैं। ##SOME STOCKS WITH GOLDEN CROSSOVER STRATEGY SOLARA JYOTICNC

PERSISTENT
DEEPAKNTR BLACKBUCK ##Bottom Line याद रखें: Golden Cross trend को confirm कर सकता है, लेकिन future की guarantee नहीं देता। यही कारण है कि इसे “Bullish Signal” समझें, “Guaranteed Buy Signal” नहीं।

See More

News & Events

Frequently Asked Questions

What is the share price of Solara Active Pharma Sciences Ltd.?

What is the market cap of Solara Active Pharma Sciences Ltd.?

Should I buy Solara Active Pharma Sciences Ltd. stock now?

What is the 52 week high and low of Solara Active Pharma Sciences Ltd.?

Is the Solara Active Pharma Sciences Ltd. stock good to buy?

Is Solara Active Pharma Sciences Ltd. a good buy for the long term?

Is Solara Active Pharma Sciences Ltd. overvalued or undervalued?

What is the PE and PB ratio of Solara Active Pharma Sciences Ltd.?

Start Now